Imprimis NJOF, LLC recalls Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC.…
- Recall date
- December 18, 2025
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-0251-2026
- FDA classification
- Class II
- Brand / firm
- Imprimis NJOF, LLC
- Sold / distributed
- U.S Nationwide
Why it was recalled
Presence of particulate matter - Glass like particles.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Get recall alerts
Free email alert whenever Imprimis NJOF, LLC has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Imprimis NJOF, LLC